ALNY price target
Alnylam Pharmaceuticals, Inc. · end-of-day data as of Oct 16, 2026
Alnylam Pharmaceuticals, Inc.
$231.83-14.7%
Buy · 30 analystsPT $374.49 +61.5%
The average price target of the 18 analyst firms that published one in the last 12 months is $374.49 for ALNY, 61.5% above the last close of $231.83 on Oct 16, 2026. Targets range from $253.73 to $492.63, with a median of $359.57. Rating consensus: Buy.
Summary
- Target upside+61.5%
- ConsensusBuy
Analyst price targets
Low$253.73
Average$374.49
Median$359.57
High$492.63
Upside+61.5%
18 firms with a target in the last 12 months · last close $231.83 · as of Oct 16, 2026
Stifel Nicolaus$5182025-12-11
H.C. Wainwright$5562025-11-04
Barclays$5352025-10-31
Chardan Capital$4822025-10-31
Oppenheimer$5072025-10-31
Morgan Stanley$4952025-10-30
+3 more
Morgan Stanley$3612026-02-13
Wells Fargo$3722026-01-20
Leerink Partners$3442025-12-15
Canaccord Genuity$4542026-02-17
Bernstein$4542026-02-13
Chardan Capital$4332026-02-13
Stifel Nicolaus$4382026-02-12
H.C. Wainwright$4972026-01-30
RBC Capital$4612026-01-20
+4 more
Bernstein$4372026-05-01
Morgan Stanley$3632026-05-01
Bernstein$3822026-08-25
H.C. Wainwright$4622026-08-04
Barclays$4822026-08-03
RBC Capital$3542026-07-31
Raymond James$4252026-07-31
H.C. Wainwright$4852026-07-13
+4 more
Jefferies$2542026-09-08
BMO Capital$3182026-08-18
Wells Fargo$2582026-08-14
Truist Financial$3132026-08-04
Morgan Stanley$3002026-07-31
Oppenheimer$3502026-07-31
+1 more
Jefferies$2342026-08-28
UBS$3692026-10-15
RBC Capital$3482026-10-08
Wells Fargo$2542026-10-14
— actual price● bullish target● bearish targethover a dot to see the analysts behind it · wheel or drag to move through time · drag the price axis on the right to stretch it · double-click resets
Strong buy 6 · Buy 17 · Hold 7 · Sell 0 · Strong sell 0